Rani Short Term Debt from 2010 to 2024

RANI Stock  USD 2.02  0.03  1.51%   
Rani Therapeutics' Short Term Debt is increasing with slightly volatile movements from year to year. Short Term Debt is predicted to flatten to about 3.6 M. For the period between 2010 and 2024, Rani Therapeutics, Short Term Debt quarterly trend regression had mean deviation of  829,071 and range of 5 M. View All Fundamentals
 
Short Term Debt  
First Reported
2010-12-31
Previous Quarter
6.3 M
Current Value
3.6 M
Quarterly Volatility
1.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rani Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rani Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 3.6 M, Depreciation And Amortization of 925.5 K or Interest Expense of 5.3 M, as well as many indicators such as Price To Sales Ratio of 130, Dividend Yield of 0.0 or PTB Ratio of 6.91. Rani financial statements analysis is a perfect complement when working with Rani Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Rani Therapeutics Correlation against competitors.

Latest Rani Therapeutics' Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Rani Therapeutics Holdings over the last few years. It is Rani Therapeutics' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rani Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Rani Short Term Debt Regression Statistics

Arithmetic Mean1,924,276
Geometric Mean1,691,869
Coefficient Of Variation70.32
Mean Deviation829,071
Median1,359,000
Standard Deviation1,353,214
Sample Variance1.8T
Range5M
R-Value0.60
Mean Square Error1.3T
R-Squared0.36
Significance0.02
Slope182,553
Total Sum of Squares25.6T

Rani Short Term Debt History

20243.6 M
20236.3 M
2021M

About Rani Therapeutics Financial Statements

Investors use fundamental indicators, such as Rani Therapeutics' Short Term Debt, to determine how well the company is positioned to perform in the future. Although Rani Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Short Term Debt6.3 M3.6 M

Currently Active Assets on Macroaxis

When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:
Check out the analysis of Rani Therapeutics Correlation against competitors.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.57)
Return On Equity
(2.25)
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.